Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Z Best Place to Talk Stocks -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (52965)	4/4/2006 7:44:01 PM
From: StockDung	Respond to of 53068

UPDATE 1-Matrixx says FTC investigating Zicam ads Tue Apr 4, 2006 9:37 AM ET NEW YORK, April 4 (Reuters) - Matrixx Initiatives Inc. (MTXX.O: Quote, Profile, Research) on Tuesday said the U.S. Federal Trade Commission was probing the company's advertising for a variety of products, including some of its Zicam cold remedies. The company, in a filing with securities regulators, said the purpose of the probe was to find whether it engaged in any unfair or deceptive acts or practices. On March 21, FTC investigators in Cleveland asked Matrixx to provide information to the agency by April 27, the company said. "The company is fully cooperating with the FTC and believes that its advertisements and promotional activities are accurate and comply with applicable laws and regulations in all material respects," Matrixx said. Phoenix-based Matrixx also said the Council of Better Business Bureaus recently said that scientific evidence substantiated Matrixx's advertising claims that using Zicam nasal gel and swabs resulted in a less severe cold. Zicam cold medicine, introduced in 1999, is the company's flagship product. Matrixx said its net income declined to $3.1 million in 2005, from $5.0 million in 2004, because of an $8.5 million charge to settle lawsuits with consumers who alleged that the medicine caused them to lose their senses of smell and taste.

To: DanZ who wrote (52965)	4/5/2006 9:06:37 PM
From: sun	Respond to of 53068

Hello Dan, How are you? Remember me???? hehehehe... "GUMM" What a coincidence! Just remembered my password and came here yesterday and today. Nice to see your post. I have always respected your posts. Hope all is well.

To: DanZ who wrote (52965)	4/10/2006 1:19:14 PM
From: Howard S.	Respond to of 53068

Still lurking and wondering where everyone went.

To: DanZ who wrote (52965)	4/27/2006 9:36:27 AM
From: Beachside Bill	Read Replies (1) \| Respond to of 53068

Get ready for the Gold dump. Time again for homebuilding...economies too strong.

To: DanZ who wrote (52965)	5/6/2006 3:26:02 PM
From: Kelvin Taylor	Read Replies (1) \| Respond to of 53068

Greetings and salutations. I logged on for the first time since last fall. Still time to make money in oil???

To: DanZ who wrote (52965)	6/17/2009 12:05:35 PM
From: StockDung	Respond to of 53068

Zicam Cold Remedy Gets FDA Warning; Matrixx Dives (Update3) By Shannon Pettypiece June 16 (Bloomberg) -- Zicam nasal sprays and swabs made by Matrixx Initiatives Inc. may cause permanent loss of smell and taste and people should stop using them, U.S. regulators said, and the company plunged the most in trading since its initial public offering. Matrixx, based in Scottsdale, Arizona, fell $13.46, or 70 percent, to $5.78 at 4:30 p.m. New York time in Nasdaq Stock Market composite trading. That’s the biggest percentage decline in one day since the IPO in April 1996. The Food and Drug Administration has received more than 130 reports of people losing their sense of smell after using zinc- based Zicam nasal spray and swabs, and Matrixx has an additional 800 reports it hasn’t made available to the agency, Deborah M. Autor, director of the FDA’s Office of Compliance, said today in a conference call with reporters. The agency told Matrixx in a letter today to stop selling three Zicam products. “If they wish to continue marketing the products, the next step is for them to come in and seek FDA approval,” Autor said. The products accounted for about 40 percent of Matrixx’s $111.6 million in sales for the fiscal year ended March 31, Matrixx said today in a statement. Matrixx said that while the products are safe, it is stopping all shipments and will issue refunds to customers. “Matrixx Initiatives stands behind the science of its products and its belief that there is no causal link between its intranasal gel products and anosmia,” the company said in an e- mail. “For this reason, Matrixx Initiatives believes that the FDA action is unwarranted and will seek a meeting with the FDA to review the company’s product safety data.” Top Seller The FDA warning applies to the Zicam Cold Remedy Nasal Gel, Gel Swabs and Kids Size swabs. Zicam, which also comes in melting tablet and liquid form, is Matrixx’s top-selling product. The FDA first received reports of a loss of smell linked to Zicam in 1999. In 2006, Matrixx agreed to pay $12 million to settle claims by 340 plaintiffs who said they lost their sense of smell after using the product. Today’s FDA letter says many homeopathic products can be sold without U.S. approval. Because of “a significant and growing body of evidence” that the Zicam products “may pose a serious risk to consumers,” the agency said Matrixx must get FDA approval to market its remedies. To contact the reporter on this story: Shannon Pettypiece in New York at spettypiece@bloomberg.net. Last Updated: June 16, 2009 17:04 EDT